Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal chemotherapy

J G Schneider1

  • 1Breast and Gynecologic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

Obstetrics and Gynecology Clinics of North America
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism.

Neurobiology of disease·2016
Same author

PPARγ population shift produces disease-related changes in molecular networks associated with metabolic syndrome.

Cell death & disease·2011
Same author

The proline 12 alanine substitution in the PPARgamma2 gene is associated with increased extent of coronary artery disease in men.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2009
Same author

Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2006
Same author

A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2004
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Intraperitoneal chemotherapy offers a promising strategy for ovarian cancer by delivering drugs directly to the peritoneal cavity, potentially improving outcomes for advanced-stage patients with persistent or relapsed disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Gynecologic Oncology

Background:

  • Advanced-stage ovarian cancer often shows poor long-term survival despite initial responses to systemic chemotherapy.
  • Recurrent or persistent ovarian cancer is frequently confined to the peritoneal cavity, suggesting a need for localized treatment strategies.

Purpose of the Study:

  • To review the pharmacokinetic rationale for intraperitoneal chemotherapy in ovarian cancer.
  • To assess the logistical feasibility of administering intraperitoneal chemotherapy.
  • To summarize clinical experiences and outcomes of intraperitoneal chemotherapy for ovarian cancer.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of pharmacokinetic data related to intraperitoneal drug delivery.

Related Experiment Videos

  • Evaluation of clinical trial results and patient outcomes.

    • Main Results:

    • Intraperitoneal chemotherapy can achieve higher drug concentrations in the peritoneal cavity compared to systemic administration.
    • Logistical challenges in administration exist but have been addressed through various techniques.
    • Clinical studies show varying but sometimes promising results for disease control and survival.

    Conclusions:

    • Intraperitoneal chemotherapy is a viable strategy for enhancing drug delivery to the peritoneal cavity in ovarian cancer.
    • Further optimization and research are needed to overcome logistical hurdles and improve patient outcomes.
    • This approach holds potential for improving disease-free survival in advanced-stage ovarian cancer patients.